MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR

Area of Science:

• Genetics
• Cancer Biology
• Molecular Biology

Background:

• Methyl-binding domain 4 (Mbd4) mutations are frequent in mismatch repair (MMR)-deficient colorectal tumors with microsatellite instability (MSI).
• The functional significance of Mbd4 mutations, often monoallelic and at poly-A tracts, remains unclear in human neoplasia.
• Previous research has not extensively explored Mbd4's role in the absence of MMR in human cancers.

Purpose of the Study:

• To investigate the significance of Mbd4 loss in the context of MMR deficiency.
• To determine if Mbd4 deficiency influences spontaneous mutation frequency, tumor onset, spectrum, or MSI in MMR-deficient mice.

Main Methods:

• Generation of Mbd4-deficient mice crossed with mice lacking DNA MMR (Msh2 or Mlh1).
• Analysis of spontaneous mutation frequency at the Dlb-1b locus.
• Assessment of tumor onset, tumor spectrum, and microsatellite instability (MSI) in genetically modified mice.

Main Results:

• Mice with combined Mbd4 deficiency and MMR deficiency showed no altered spontaneous mutation frequency at the Dlb-1b locus compared to singly mutant mice.
• Loss of Mbd4 did not modify tumor onset, tumor spectrum, or MSI in the context of MMR deficiency.
• Nullizygosity or heterozygosity for Mbd4 did not affect MMR-dependent tumorigenesis in the studied mouse models.

Conclusions:

• Mbd4 deficiency does not exacerbate or alter tumorigenesis in the absence of functional DNA mismatch repair.
• These findings indicate that Mbd4 is not a critical factor in MMR-dependent cancer development.
• The study clarifies the limited role of Mbd4 in MMR-deficient tumorigenesis.